Sygnis Bioscience GmbH & Co KG Report issue

For profit Phase 2
Founded: Heidelberg Germany (1997)
Status: Acquired by Expedeon (2017)

Organization Overview

First Clinical Trial
2009
NCT00927836
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (2)

Key: Sygnis Bioscience GmbH & Co KG (1) Acquired (1)

sargramostim (leukine) (2 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cerebral Infarction (Phase 2)

Ischemia (Phase 2)

Stroke (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2